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1. Introduction
1.1 Chronic Periodontitis (CP)
1.1.1 Bacterial etiology of CP
Chronic periodontitis (CP) is a bacterial-driven inflammatory disease that affects the tooth
supporting connective tissues. This condition results from the interaction of specific bacterial
communities with the immune response of susceptible individuals [1]. The composition and
organization of dental biofilms are key factors that dictate the survival/proliferation of certain
species at the expense of others and, in general, define periodontal health and disease states [2,
3]. Specifically, while subgingival plaque samples from periodontally healthy patients comprise
mainly aerobic Gram-positive rods or coccoid species, samples from CP patients depict a shift
towards anaerobic Gram-negative rods and motile spirochetes [4-9]. In particular, Gram-positive
rods such as Actinomyces naeslundii and Actinomyces viscosus are typical species found in
healthy sites [4, 9, 10]. On the other hand, Aggregatibacter actinomycetemcomitans [1, 5, 7],
Fusobacterium nucleatum [1, 6, 9, 10], Tannerella forsythia [1, 7, 11, 12], Campylobacter rectus
[1, 5], Porphyromonas asaccharolytica [7], Prevotella melaninogenica [6, 8, 9], Porphyromonas
gingivalis [1, 8, 10-12], Prevotella intermedia [1, 5, 8, 10], as well as the spirochete Treponema
denticola [11, 12] have been all correlated with diseased sites. Furthermore, elevated counts of A.
actinomycetemcomitans and P. intermedia have been found in sites with bleeding on probing
(BoP) [5, 13], a clinical indicator of periodontal inflammation. Additionally, high proportions of
F. nucleatum and Campylobacter rectus were more prevalent in active sites [5], whereas
increased P. gingivalis [13, 14] counts have been found in deep pockets of CP patients.
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For many years, bacterial culture was considered the gold standard assay to isolate and classify
periodontal bacteria. This method is useful in establishing associations between diseases and
certain microbes. In fact, as mentioned before, many known and un-named periodontopathogens
were detected using selective and non-selective culture analyses from severe and chronic
periodontitis patients. These studies allowed for the description of several taxa at species and
sub-species levels [15, 16]. However, not all bacteria detected by the microscope can be grown
in culture media. Moreover, culture-independent techniques have proven that microscopy and
culture studies are incapable of clustering bacteria into similar phylogenetic groups [17-20].
Consequently, gene-derived methods were developed to overcome the limitations of culture
studies.

In particular, PCR amplification of the bacterial 16S rRNA gene, followed by cloning and
sequencing has been used to describe oral bacteria [19-21]. This strategy revealed that 40% of
the 327 species predicted to exist in the subgingival environment are uncultured [19]. An
advantage of this technique is the fact that universal primers can be designed to quantify the total
number of species of a sample [17, 19, 22]. Ribosomal RNA has been targeted due to its
ubiquity, but preserved sequence variation; the former of which allows for accurate alignment,
while the latter permits phylogenetic analysis [23, 24]. Specifically, the first two variable regions
(V1 & V2) of the 16S rRNA gene result in improved power analysis in terms of number of
phylotypes detected [25]. For microbial identification, the amplified sequences are then
compared to database references [26, 27] at a suggested 97% sequence homology [28].
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Studies employing cloning and sequencing of the bacterial 16S rRNA gene allowed the
identification of non-cultivable species in CP [19, 29, 30]. These molecular technologies
demonstrated that known pathogens such as P. gingivalis, T. forsythia, and T. denticola comprise
only a minor portion of the subgingival plaque [19]. Cloning revealed a novel Veillonella X042
phylotype associated with periodontal health, while Filifactor alocis, a Gram-positive anaerobe,
as well as some phylotypes of Selenomonas (CS015, CS002, FNA3) [18, 31], Treponema
(VI:G:G47, Smibert-5) [31], and Pepstreptococcus [18] have been correlated with periodontal
disease.

More recently, a new sequencing technique, namely pyrosequencing, was developed, which
obviates the need of plasmid cloning after PCR amplification. Pyrosequencing utilizes the
detection of nucleotide incorporation during synthesis by pairing pyrophosphate release to a
chemiluminescence signal [32]. Another advantage of pyrosequencing is its ability to generate a
high number of sequences by emulsion PCR (emPCR), which can be sequenced simultaneously
in a timely manner. This is particularly advantageous for the identification of phylotypes present
in heterogeneous samples [33-36]. Different methods can be applied when pyrosequencing is
used. Specifically, one bi-directional and two uni-directional sequencing methods were
compared after 10 environmental samples were analyzed. Results showed that uni-directional
sequencing produced increased reads (1.5-1.6 times higher than bi-directional sequencing)
without compromising the outcome of microbial community analyses [37].
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Pyrosequencing has been utilized in a few studies to evaluate the microbiome of CP patients [38,
39]. Amplicons from the 16S rRNA hypervariable regions V1-V2 and V4 were sequenced from
plaque samples of healthy and CP patients (shallow and deep pockets). The main diseaseassociated phyla comprised Spirochaetes, Synergistetes, Bacteroidetes, and Firmicutes (Class
Clostridia, Class Negativicutes, Class Erysipelotricha), while health-associated phyla were
Proteobacteria and Firmicutes (Class Bacilli). The authors reported a significant difference in
the community profiles when healthy sites were compared to shallow and deep pockets from CP
patients. In particular, CP samples from deep pockets showed a tendency towards increased
numbers of uncultivable species as well as elevated richness and evenness (Shannon index).
Interestingly, P. gingivalis and T. denticola were associated with disease states as much as the
Gram positive Filifactor alocis, while T. forsythia only ranked as the 16th most abundant diseaseassociated organism [38]. Similarly, another study sequenced plaque samples aiming at assessing
the relationship between inflammation (i.e presence of BoP) and the subgingival microbiome in
CP, as well as evaluating differences in the microbiomes in health and disease Results showed
that increased total microbial load and richness, as well as a shift in the subgingival communities
were associated with periodontal destruction, but not with sites that bled upon probing.
Periodontitis-prevalent operational taxonomic units (OTUs) included Treponema spp.,
Bacteroidetes spp., Synergistetes spp., Chloroflexi spp., OTUs from the TM7 phylum, and many
OTUs from the Clostridia class (Firmicutes phylum). On the other hand, Actinomyces spp.,
Streptococcus spp., Proteobacteria, and certain Porphyromonas spp. were related to health [39].
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1.1.2 Host response in CP
The shift from a healthy flora to a pathogenic one has dramatic implications on the immune
system of the host. The inflammatory process seen in CP patients is characterized by the
recruitment of an intense cellular infiltrate into the periodontal connective tissue. This infiltrate is
mainly composed of plasma cells, B and T-cell lymphocytes, polymorphonuclear leukocytes
(PMNs), monocytes, and macrophages (Figure 1) [40, 41]. As a consequence, an increased
production and activation of host-derived enzymes, associated with an exacerbated inflammatory
response, is followed by a gradual destruction of the tooth supporting connective tissues [42, 43].

50%	
  
40%	
  
30%	
  
20%	
  
10%	
  
0%	
  

Figure 1. Proportions of cells in CP lesions. Plasma cells dominate, followed by B and T
cells, while polymorphonuclear neutrophils (PMNs) and macrophages represent only a minor
portion of immune cells. Other cells: fibroblasts, mast cells, and unidentified cells (adapted from
[41]).
Periodontopathogens have the ability to attach to cells/surfaces to invoke microbe-host
interactions, invade and grow within host tissues, as well as evade or interfere with host defenses

5

[42, 44]. Attachment to extracellular matrix, other microbial species, and host cells (i.e.:
epithelial cells, gingival fibroblasts) is attained through surface appendages called fimbriae [4547]. This first interaction stimulates toll-like receptors 2 (TLR-2) and 4 (TLR-4) on epithelial
cells, fibroblasts, and macrophages, which in turn induces the production of the proinflammatory cytokines interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1ß), interleukin-6 (IL6), and tumor necrosis factor alpha (TNF-α) [48-52]. Some bacteria are also capable of invading
epithelial cells, endothelial cells, and fibroblasts as a means to evade the host’s immune response
[53-55]. This is the case of P. gingivalis, which uses fimbriae (FimA) and cysteine proteinases
called gingipains to be internalized by epithelial cells and escape from the host’s defense [29,
42]. Gingipains can also inhibit PMN bactericidal activity [56] and migration [57], inactivate
complement C5a receptor of neutrophils [58, 59], and degrade immunoglobulins (Ig) IgG, IgA,
and IgM [29, 60].

Other bacterial virulence factors such as lipopolisaccharides (LPS), peptidoglycans (PGN), and
lipoteichoic acid (LTA) stimulate the secretion of IL-1ß, TNF-α, IL-6, and IL-8 by epithelial
cells. Diffusion of these and other cytokines into the gingival connective tissue causes direct or
indirect stimulation of leukocytes, fibroblasts, mast cells, endothelial cells, dendritic cells, and
lymphocytes [61-65]. Stimulated host cells release vasoactive molecules (TNF-α, prostaglandin
E2 – PGE2, histamine), increasing the concentrations of exudative fluid proteins in the
connective tissue and gingival crevicular fluid (GCF). In addition, leukocyte migration through
the tissues is prompted by either bacterial (i.e.: formyl-methionyl-leucyl-phenylalanine - fMLP,
fimbriae) or host chemoattractants (i.e.: monocyte chemotactic protein-1 - MCP-1, IL-8) [66-68].
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As an attempt to create space for the inflammatory infiltrate (exudate and leukocytes), fibroblasts
activated by IL-1ß, TNF-α, and PGE2 secrete matrix metallo-proteinases (MMPs) that degrade
collagen from the connective tissue compartment [69-71].

CP can also elicit a systemic response since severe CP patients express elevated serum levels of
inflammatory mediators. For instance, periodontally-derived cytokines (i.e.: IL-1ß, TNF-α, and
IL-6) may reach the liver and activate hepatocytes to produce complement proteins and acutephase proteins such as lipopolysaccharide binding protein (LBP) and C-reactive protein (CRP),
which facilitate bacterial phagocytosis by opsonization [63, 70].

Overall, periodontal connective tissue and bone destruction result from the interaction of
pathogenic bacterial communities with the host, leading to increased levels of inflammatory
cytokines and tissue-destructive molecules (i.e.: MMPs, PGE2, and IL1-ß) against low levels of
anti-inflammatory cytokines [72].
1.1.3 Effects of non-surgical periodontal therapy on the oral microbiome and clinical
parameters of CP patients
Oral bacteria inhabit highly organized complex ecosystems called dental biofilms, which are also
composed of bacterial products, proteins, an extracellular matrix of polysaccharides, and
inorganic matter [73, 74]. Dental biofilms act as a distinct entity that provides an environment
where bacteria can thrive while protected from the host defense and topical antimicrobial
therapy. In this context, mechanical removal of irritants from teeth surfaces becomes paramount
for successful periodontal treatment. Hence, scaling and root planing (SRP) represents the most
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commonly employed form of periodontal therapy in both the initial and maintenance phases of
treatment. This non-surgical therapy is designed to remove hard and soft deposits from tooth
surfaces above and below the gingival margin [75-77].

The effect of SRP on the oral microbiota and clinical parameters of CP patients has been
reported in many studies [78-80]. Beneficial outcomes include reduction in clinical inflammatory
parameters/indices (i.e.: BoP, attachment loss - AL, plaque index - PI, gingival index - GI,
pocket depth - PD) and pathogenic microbial counts from pre- to post-SRP.

Culture analyses from periodontal pockets have shown an association between decreased counts
of red complex members (i.e.: P. gingivalis, T. forsythia, and T. denticola) [81, 82] and
decreased GI and PD after initial therapy [13, 82]. Also, most treated sites have been correlated
with a decrease in the prevalence of P. gingivalis [13, 83], A. actinomycetemcomitans [83] and P.
intermedia [83, 84] and an increase in A. viscosus [82]. Microscopy-based studies have shown
that post-treatment proportions of spirochetes and total motile bacteria are reduced at the expense
of the elevation on the prevalence of cocci [85].

A DNA-DNA checkerboard evaluation for 40 microbial species showed similar results to the
microscopic/culture studies described above. Specifically, PD, BoP, AL, and plaque
accumulation decreased significantly with increasing post-treatment levels of Actinomyces spp.
and decreasing prevalence of T. forsythia and P. gingivalis. In addition, a strong association was
found between decreases in both pocket depth and proportions of T. forsythia [86]. Clearly, one
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of the more significant effects of SRP is to favor the prevalence and increased proportions of
beneficial species, which might decrease the injurious effects derived from the presence of more
pathogenic phylotypes, and decrease the abundance and prevalence of pathogenic species. No
study, however, has evaluated the response to periodontal therapy using a global-scale
microbiological approach. It is thus not clear if initial therapy radically changes the whole
community towards one compatible with health.

1.2 Periodontitis and Chronic Kidney Disease (CKD)
Proper kidney function is crucial for homeostasis, blood filtration, and the production of essential
hormones. Specifically, renal function regulates blood concentrations of ions, urea, glucose, and
stimulates the production of hormones such as calcitriol, renin, and erythropoietin. As a result,
electrolyte and blood pressure control, acid-base balance maintenance, and erythropoiesis are
achieved [87]. In chronic kidney disease (CKD), renal function loss causes accumulation of
water, waste, and toxic substances, which may result in conditions such as anemia, hypertension,
acidosis, disorders of cholesterol and fatty acids, and bone disease. Once the extent of renal
damage is past the point of compensation, patients develop end-stage renal disease (ESRD) and
the treatments of choice are dialysis or kidney transplantation [88].

CKD has been classified in five stages, with stage 1 being the mildest and usually causing few
symptoms and stage 5 being a severe illness with poor life expectancy if untreated (Table 1).
Based on the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
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Guidelines, patients with CKD stage 5 are treated with hemodialysis (HD) when the weekly
renal urea clearance falls below 2.0, which is a sign of uremia [89].

Table 1. Stages of Chronic Kidney Disease
Stage

Description

1
2
3
4
5

Slight kidney damage with normal or increased filtration
Mild decrease in kidney function
Moderate decrease in kidney function
Severe decrease in kidney function
Kidney failure

Glomerular filtration
rate (mL/min/1.73m2)
More than 90
60-89
30-59
15-29
Less than 15 (or dialysis)

One of the major aspects of CKD is an immune depletion state, which can be caused by
underlying conditions that led to renal failure (i.e. diabetes mellitus, vascular disease), uremia or
therapy (i.e. dialysis and transplantation) [90]. Such immuno-incompetence may derive from
defective antigen recognition [91] and antibody formation [92], as well as impaired neutrophil
function [93-96]. Therefore, mainly two cell types are involved in the immunodeficiency seen in
CKD: lymphocytes and phagocytes. Specifically, serum accumulation of toxins has been shown
to alter the activation of monocytes, B- and T-cells [91, 97-99], and neutrophils [93-96].

The accumulation of toxic substances in the uremic plasma has been reported to promote
abnormal superoxide production [93-96], decreased neutrophil chemotaxis [93, 96, 100],
phagocytosis [94, 95, 101], and intracellular killing [93, 95]. As a result, these patients present an
increased susceptibility to infections [91, 92, 97], having elevated mortality rates from sepsis
[90, 102].
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On the other hand, the production of cytokines that activate B- and T-cells (IL-2 and INF-γ) is
reduced in CKD patients [103-105]. However, it has been shown that there is no intrinsic defect
on T-cells. Rather, an insufficient co-stimulatory effect of the antigen presenting cells (APCs; i.e.
monocytes) was found to play a role in the impaired activity of lymphocytes [99, 106]. For
instance, T-helper cells (or CD4+ cells) recognize and amplify the signals from APCs and can
develop into either Th1 or Th2. Th1 cells produce interferon-gamma (INF-γ) and promote
cellular effector function, while Th2 cells are accessory to B-cells for immunoglobulin
production [107]. Both Th1 and Th2 are present in low numbers in dialysis patients, but CKD
patients show an increased tendency for Th1 differentiation. Such bias towards Th1 development
is due to increased levels of IL-12 produced by APCs/monocytes [105], which results in even
less B-cell activity. In addition, uremia and HD interfere with monocyte function because of
repeated complement activation. In this millieu, monocytes are required to produce high levels of
the pro-inflammatory cytokines IL-1 and IL-6. However, this chronic activation leads to immune
failure when no active infection is present since high levels of pro-inflammatory cytokines result
in low T-cell activation [90].

All in all, the proneness of infection seen in CKD patients is a result of hampered cellular and
humoral mechanisms. Monocytes, macrophages, B- and T-cells are affected, which render the
host ineffective in producing adequate responses to bacterial/inflammatory insults [97, 108].
1.2.1 CP prevalence in CKD patients
Both CKD and CP are characterized as inflammatory diseases that compromise the host’s
immunologic response and have drastic systemic implications [109-112]. In this context,
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associations have been made in the literature, which speculate a predisposition of CKD patients
to periodontal disease. However, evidence on the prevalence of periodontitis in the CKD
population has been conflicting. While some studies showed no difference in the prevalence of
periodontitis between the general and the CKD population [113-115], others showed a higher
prevalence of CP in the CKD patients [116-119]. These controversial results may be due to
discrepancies in study designs (i.e. lack of controls, CP and CKD definition) and bias (i.e. failure
to account for confounding factors).

Recent evidence, nevertheless, gives credence to a strong correlation between CP and CKD [119,
120]. For instance, in a study that examined the prevalence of CP in CKD patients, it was found
that CKD patients had significantly more CP when compared to non-CKD controls (14.7%
versus 8.7%). Furthermore, Mexican-Americans and non-Hispanic Blacks with CKD showed
increased odds ratios for CP (OR 1.70 and 1.30, respectively) after statistically adjusted for age,
sex, smoking, diabetic status, control and duration, as well as for body mass index (BMI),
cardiovascular disease, and hypertension [119]. Another study used multivariate logistic
regression models to control for 14 potential CKD risk factors and showed diabetes duration and
hypertension as indirect mediators between CP and CKD. These results were further tested by
structural equation models, which not only corroborated diabetes duration and hypertension as
mediators of the effect of CP on CKD, but also demonstrated a bidirectional relationship
between CP and CKD [120].
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1.2.2 Microbiome of CKD patients
As stated above, the inter-relationship CP-CKD may derive from the increased proneness of
CKD patients to microbial infection and its related inflammatory challenge. Therefore, it seems
reasonable to expect that CKD patients would present increased levels/proportions of
periodontopathogenic bacteria.

A recent study evaluated the severity of CP in patients with and without CKD by examining
clinical parameters (PD and AL) and plaque samples by polymerase chain reaction (PCR)
analysis

using

16S/18S

rRNA

primers

for

Candida

albicans,

F.

nucleatum,

A.

actinomycetemcomitans, Prevotella nigrescens, P. intermedia, Eikenella corrodens, P.
gingivalis, T. denticola, and T. forsythia. Results showed that CP was more severe in CKD
patients compared to non-CKD patients. Also, an association was found between clinical
attachment levels and the prevalence of C. albicans, P. gingivalis, and T. denticola in CKD
patients with CP. Statistically significant higher frequencies of C. albicans, P. gingivalis, T.
forsythia, and T. denticola were found for CKD compared to non-CKD subjects. This work,
however, failed to control for important confounding factors such as diabetes and hypertension
[121].

Interestingly, a PCR evaluation of plaque from hemodialysis patients reported increased levels of
P. gingivalis, T. forsythia, and P. intermedia compared to age and sex-matched controls.
However, increased levels of periodontopathogenic bacteria were not correlated with attachment
loss and end-stage renal disease (ESRD) was not associated with more severe periodontal
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destruction [114]. Similarly, increased BANA test scores for red complex bacteria were found in
shallow to moderate pockets (3-5mm) of CKD patients, while equivalent scores were seen in
deep pockets (>5mm) of matched controls with periodontitis. However, despite having increased
plaque and calculus accumulation indices, CKD patients showed decreased PD compared to
Control patients with periodontitis [122].

These limited studies suggest that CKD may predispose the host to harbor increased levels of
periodontal pathogens. Impaired immune responses, however, may be responsible for a lack of
correlation between these increased levels and periodontitis severity.
1.2.3 Effects of non-surgical periodontal therapy on the oral microbiome and clinical
parameters of CKD-CP patients
The reported increased levels of periodontopathogens allied with the elevated CP prevalence in
CKD patients underscore the importance of periodontal treatment to control infection in these
patients. Periodontal treatment success should be measured not only by improvements in clinical
parameters (i.e. PD, GI, PI, AL), but also by analysis of microbiological outcomes.

The importance of effective periodontal treatment in CKD patients is further highlighted by the
fact that CP may contribute to the chronic inflammation present in CKD [123], as well as to
other inflammatory conditions such as cardiovascular diseases (CVD) [124-127] and diabetes
mellitus (DM) [128-131]. This is believed to be due to the systemic diffusion of pathogenic
bacteria and their products. For instance, P. gingivalis, A. actinomycetencomitans, P. intermedia,
T. denticola, and E. corrodens have been found in atherosclerotic plaques [54, 132]. Bacterial
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contact with and invasion of the endothelium induce the expression of intercellular adhesion
molecule (ICAM), vascular cell adhesion molecule (VCAM), IL-8, IL-6, MCP-1, and TLR-4
[52, 133, 134].

Although many studies evaluated the effect of SRP in subjects with other chronic inflammatory
conditions, only two studies were found which examined the outcomes of SRP in CKD patients
[113, 135]. In Artese et al. [113], the response of 21 pre-dialysis subjects with CP to SRP was
compared to that of 19 systemically healthy patients with CP matched for gender, BMI,
ethnicity, and smoking status. Non-CKD patients with CP responded similarly to CP-CKD
patients. Specifically, a significant decrease in gingival bleeding, visual plaque, suppuration,
BoP, PD, and AL with no difference between the groups was seen at 3 months post-SRP. In
addition, statistically increased GFR (as assessed by the Cockcroft and Gault equation) was
found for both groups [113]. However, CKD subjects in this study were in the pre-dialysis stage
and perhaps were yet to develop the severe uremic state seen in dialysis patients, which may
compromise immune responses and wound healing. Furthermore, this study did not include a
comparative assessment of the microbiomes of the two populations.

Another study from the same authors is the only work that analyzed the clinical and
microbiological outcomes of SRP in CKD-CP and CP patients [135]. At 3 months post-SRP both
groups showed significant clinical improvements as assessed by PD, CAL, and visual plaque.
DNA-DNA hybridization was performed to evaluate the presence and levels of 49 species. At
baseline, the periodontitis-associated subgingival microbiota of CKD and CP had similar
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composition. Enterococcus faecalis was the only species detected in higher counts in CP patients
compared to CKD-CP. At 3 months post-SRP, there was a significantly decreased level of most
species on the CP group, but only Actinomyces gerencseriae, Actinomyces oris, A.
actinomycetemcomitans,

Fusobacterium

nucleatum

ssp.

polymorphum,

Streptococcus

constellatus, Leptotrichia buccalis, Dialister pneumosintes, enterics, and Staphylococcus aureus
decreased in the CKD-CP group. Moreover, Prevotella nigrescens increased post-therapy in the
CKD-CP group. CKD-CP patients also presented increased post-SRP levels of Actinomyces
israelii, C. rectus, Fusobacterium periodonticum, Parvimonas micra, Prevotella nigrescens, T.
forsythia, Neisseria mucosa, and Streptococcus anginosus when compared to the CP control
group post-therapy Furthermore, sites that lost attachment after SRP in CKD-CP patients showed
increased levels of T. forsythia, P. gingivalis, T. denticola, and Fusobacterium spp. when
compared to sites that responded well to initial periodontal therapy. Overall, the authors found
persistent high levels of many pathogenic bacteria in CKD-CP patients and hypothesized a
correlation between uremia and the immunocompromised state of these patients with a rapid recolonization by pathogenic species after non-surgical periodontal therapy. No study, however,
has used pyrosequencing of 16S rRNA amplicons or another global approach to compare the
response to SRP in CKD patients.
1.3 Rationale
In summary, periodontal disease is an inflammatory-infectious condition caused by changes in
the subgingival microbiome that culminate in destruction of the tooth-supporting tissues. This
disease has been shown to contribute to an elevated systemic burden by the release of proinflammatory cytokines, which in turn may exacerbate the inflammatory state of CKD patients.
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Hence, efficacious treatment of CP is of utmost important in this population. However, the
uremic state of CKD subjects may predispose them to increased periodontal destruction, either
by modifying the infection burden or the inflammatory responses. Compromised immune
responses and wound healing in CKD patients could also compromise the response to
periodontal therapy. The literature investigating possible differences in the infection burden in
the subgingival environment in CKD patients is scarce with available studies indicating either
some differences in carriage of periodontopathogens or no difference. No study however, has
evaluated potential differences in the subgingival microbiome between CKD and control patients
using a global-scale approach. Similarly, only a few studies, with controversial outcomes, have
evaluated the clinical response of CKD patients to periodontal therapy and no study has
evaluated microbiological outcomes at a global scale. Therefore, in this study we will compare
the clinical and microbiological profiles of CKD patients and controls with chronic periodontitis
at baseline and after initial therapy, evaluating the subgingival microbiome via high throughput
sequencing. This study will allow us to better understand the interaction between host and
bacterial insult in CKD, potentially deconvoluting the mechanisms through which CKD and CP
correlate.

2. Objectives
2.1 Specific aims
Aim 1. To compare the subgingival microbiome composition of non-CKD (Control) and
CKD subjects with CP.
Aim 2. To evaluate and compare the clinical and microbiological response to nonsurgical periodontal treatment in non-CKD (Control) and CKD subjects with CP.
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2.2 Hypotheses
The presence of CKD alters the colonization patterns of oral microorganisms during CP and
affects the response and microbiological outcomes after periodontal therapy. Therefore, our
hypotheses are that:
Different microbiomes are associated with CP in CKD compared to Control patients.

Control and CKD patients with CP will show similar improvements in periodontal clinical
parameters, but pathogen microbiota reduction from pre- to post-SRP will be limited for CKD
patients with CP compared to Control patients with CP.

Null Hypothesis 1: There is no difference between the microbial profiles of CKD and Control
patients with CP.
Null Hypothesis 2: There is no difference in the clinical and microbiological response to nonsurgical periodontal therapy for Control and CKD patients with CP.

3. Study design and methods
To achieve the above-described objectives, plaque samples were collected before and after nonsurgical treatment for CP. The microbiome composition of these samples was then determined
by high-throughput 454 pyrosequencing of the bacterial 16S rRNA gene. Clinical baseline
parameters and their change in response to periodontal treatment were also evaluated.
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3.1 Study populations
Two subject cohorts were included in this study. The first group comprised patients with CKD
and CP, who were recruited from the University of Connecticut Dialysis Center (UCDC), the
Springfield Dialysis Center in Springfield, Massachusetts, and other dialysis centers in the
surrounding area including Dialysis Units in Newington, Forestville, Southington, Agawam and
Chicopee. The second group included Control patients with CP, who were referred for
periodontal treatment to the Periodontology Graduate Clinic at the University of Connecticut
Health Center (UCHC). Table 2 shows the inclusion and exclusion criteria for the cohorts of this
study, while Table 3 shows a specific exclusion criterion for CKD patients with CP and
exclusion criteria for Control patients with CP.
Table 2. Inclusion/exclusion criteria for CKD and Control patients with CP.
Inclusion criteria

Exclusion criteria

• At least one site with probing depth (PD) of 5mm
or more and two or more interproximal sites with
clinical attachment loss (CAL) equal or more than
6mm [136];

• Inability or unwillingness to follow the study
protocol;

• A minimum of 15 teeth;
• No history of antibiotic use within the last month,
and

• Severe co-morbid conditions likely to affect life
expectancy within 1 year (for example, metastatic
cancer), and
• Dementia, pregnancy or lactation, and smoking.

• No history of periodontal treatment within the last
year.

Table 3. Specific exclusion criteria for Control and CKD groups.
Exclusion criterion for CKD patients with CP
• History of vascular access infection or clotted
access within the last month.

Exclusion criteria for Control patients with CP
• Systemic diseases that are not controlled (i.e diabetic
or hypertensive patients with cardiovascular disease
not taking medications to control their condition),
and
• Immunocompromising conditions such as HIV,
rheumatoid arthritis, CKD or history of
chemotherapy or radiotherapy (in the previous five
years).
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3.2 Clinical study design
3.2.1 Control patients with CP
Control patients with CP were recruited from subjects undergoing initial phase of periodontal
treatment in the Periodontology Graduate Clinic at UCHC. Subjects were seen for at least four
visits. The first visit included patient screening and orientation, followed by informed consent
signature. Medical history and periodontal clinical parameters were also collected. The second
visit occurred at the time of initial periodontal treatment (SRP), at which time plaque samples
were collected. At the third visit, initial periodontal treatment was completed. Finally, the fourth
visit was booked at the re-evaluation exam (2 months after SRP), when retrieval of plaque
samples and documentation of the final clinical parameters were conducted (Figure 2).
Control subjects with
CP

Visit 1

Visit 2

Visit 3

- Medical history

- Plaque
collection

- Periodontal
examination

- Scaling and
root planing

- Completion of
non-surgical
periodontal
therapy

Visit 4 (2mo after
SRP completion)

- Plaque collection
- Periodontal
examination

Figure 2. Schematic representation of study design and visit procedures. Visit 1 included analysis of
medical history and periodontal examination. Plaque collection as well as scaling and root planing
were performed in visit 2. Visit 3 encompassed completion of non-surgical periodontal therapy. Visit
4 consisted of plaque collection and periodontal examination.
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3.2.2 CKD patients with CP
CKD patients with CP were recruited from the various dialysis centers as previously described.
This group was subjected to one pre-screening visit prior to the visits described for Control
patients with CP. This visit (visit 0) included an analysis of whether subjects fit into the inclusion
and exclusion criteria by their primary provider (nephrologist) to determine initial eligibility for
the study (Figure 3).
CKD subjects
with CP

Visit 0
- Pre-screening
with nephrologist

Visit 1

Visit 2

Visit 3

- Medical history

- Plaque
collection

- Periodontal
examination

- Scaling and
root planing

- Completion of
non-surgical
periodontal
therapy

Visit 4 (2 months
after visit 2)

- Plaque collection
- Periodontal
examination

Figure 3. Schematic representation of study design and visit procedures. Visit 0 included prescreening of CKD patients by their nephrologists. Visit 1 included analysis of medical history and
periodontal examination. Plaque collection as well as scaling and root planing was performed in visit
2. Visit 3 encompassed completion of non-surgical periodontal therapy. Visit 4 consisted of plaque
collection and periodontal examination.
3.3 Clinical study procedures and sample collection
3.3.1 Visit 0 (Pre-screening and nephrologist consultation for CKD patients with CP)
Before starting their periodontal treatment, CKD patients with CP were subjected to a prescreening and a consultation with their primary provider (nephrologist). At this stage, the
nephrologist determined initial eligibility for the study based on criteria 3 (no history of
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antibiotic use within the last month) and 5 (no history of vascular access infection or clotted
access within the last month).
3.3.2 Visit 1 (Screening and initial periodontal examination)
Procedures of this appointment included review of medical history and a full mouth periodontal
examination, which was performed at six sites per tooth as follows:
• Plaque score (PS): presence or absence of plaque was measured with the use of disclosing
solution. Scores were stratified as 0: no plaque; 1: presence of plaque. Percentage of sites with
plaque was then calculated for each subject [137];
• Pocket probing depths (PD): distance in millimeters from the gingival margin to the base
of the pocket upon gentle probing with a Michigan probe;
• Bleeding on probing (BoP): presence or absence of bleeding after gentle probing.
Percentage of bleeding sites was then calculated for each subject, and
• Clinical attachment levels (CAL): distance in millimeters from the cemento-enamel
junction to the base of the pocket using a Michigan probe.

3.3.3 Visits 2 (plaque collection; initial periodontal therapy) and 3 (completion of nonsurgical therapy)
Plaque samples were collected at the time patients presented for initiation of periodontal therapy
(SRP). Subjects were asked not to eat or drink for 1 hour prior to the study visit. Plaque was
collected from the deepest pocket in two different quadrants and the two samples pooled.
Collection procedures involved removal of supragingival plaque with a curette and sampling of
subgingival plaque with individual sterile Gracey curettes. Plaque samples were immediately
placed in a polypropylene tube containing 50µl Tris-EDTA (TE) buffer and stored at -80ºC.
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After plaque collection, patients received initial periodontal therapy, which involved SRP
performed according to regular standard of care. Some patients required 2 visits to complete
initial periodontal treatment (visits 2 & 3).
3.3.4 Visit 4 (Sample and clinical data collection after periodontal therapy)
Visit 4 was booked at 2 months after completion of initial periodontal treatment. Plaque samples
were collected and stored at the beginning of the visit in the same manner as described in visit 2.
Next, a full mouth periodontal examination was performed and recorded using the same
approach described for visit 1.
3.4 Microbiological laboratory procedures
For microbiological analysis, DNA was isolated from plaque samples resuspended in buffer.
DNA was used as a template for triplicate PCR reactions with universal primers for the V1 and
V2 regions of 16S rRNA gene. Microbial amplicon libraries were then sequenced with titanium
454 pyrosequencing chemistry (Figure 4).

Plaque

DNA isolation

Microbiome
determination
(454 pyrosequencing)

Figure 4. Sampling strategy: plaque samples were used for isolation of bacterial DNA, which
was used for amplicon library preparation and sequencing by titanium 454 pyrosequencing.
3.4.1 DNA isolation
Subgingival plaque samples were collected and placed in 50µl of Tris-EDTA (TE) buffer.
Samples were re-suspended in lysis buffer with lysozyme at 37°C for 30 minutes. Next,
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proteinase K and AL buffer (Qiagen DNA extraction kit) were added and incubated at 56°C
overnight. Inactivation of proteinase K was performed by heating the suspension at 95°C for 5
minutes. DNA isolation was performed using the Qiagen DNeasy Blood and Tissue kit (Qiagen,
Valencia, CA) by following the manufacturer’s instructions. The final solution was eluted in
50µl of MD5 solution (MoBio) and DNA concentration was measured using a Nanodrop
instrument (ND-1000; light spectrophotometry at 260nm). Positive controls (180µl of a known
bacterial culture) and negative control samples for the assessment of sample contamination by
foreign DNA (180µl of lysis and TE buffers without any sample) were also included.
3.4.2 Microbiome determination using 454 pyrosequesencing
Amplicon libraries were prepared using fusion primers with adaptor primers “A” and “B” (Table
4), universal primers (Table 5), and 13 different multiplex identifier tags (MIDs – Table 6). A
schematic representation of the fusion primers is shown in Figure 5. These primers amplify a 425
bp fragment covering the regions V1 and V2 of the 16S rRNA gene.
PCR was performed in thin-walled tubes with a C1000 Touch Thermocycler (BioRad, Hercules,
CA). Each reaction was performed in triplicate using a total volume of 25µl containing 5µl of
DNA template, 2.5µl of 10X PCR buffer, 0.75µl of MgCl2, 0.5µl of deoxynucleoside
triphosphates (dNTPs 10mM), 0.125µl of Taq polymerase, 15.625µl of PCR water and 0.25µl of
each primer. PCR conditions were as follows: pre-heating of samples at 95°C for 3 minutes,
denaturation at 95°C for 30 seconds, annealing at 50°C for 30 seconds, and elongation at 72°C
for 60 seconds. In total, 25 cycles were conducted, which were followed by a final elongation
step at 72°C for 9 minutes. Reaction products were evaluated by gel electrophoresis (1.5%
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agarose gel run at 100V for 20 minutes), DNA was stained using ethidium bromide and
visualized under short-wavelength UV-light (Gel-Doc system, BioRad). The Qiagen PCR kit
was used to purify PCR products. Finally, amplicon library quantification was also conducted
using Experion DNA chip (BioRad, Hercules, CA) and bacterial amplicon libraries sequenced
with titanium 454 pyrosequencing chemistry.
Tables 4, 5 & 6. List of fusion primers used for pyrosequencing. Adaptor sequences are shown
in table 4, universal primers are displayed in table 5, and MIDs are listed in table 6.
Table 6
Table 4
Adaptor sequences A and B
5’-CCATCTCATCCCTGCGTGTCTCCGACTGAG-3’
5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3’

Table 5
Universal primers
Forward 5’-AGAGTTTGATCMTGGCTGAC-3’
Reverse 5’-CYIACTGCTGCCTCCCGTAG-3’

MIDs
ACGAGTGCGT
ACGCTCGACA
AGACGCACTC
AGCACTGTAG
ATCAGACACG
ATATCGCGAG
CGTGTCTCTA
CTCGCGTGTC
TAGTATCAGC
TCTCTATGCG
TGATACGTCT
CATAGTAGTG
CGAGAGATAC

Adaptor A MID Forward primer
V1

V2

V1

V2
Reverse primer MID Adaptor B

Locus specific
PCR amplification (425bp)

Adaptor A MID Forward primer

V1

V2

Reverse primer MID Adaptor B

Adaptor A MID Forward primer

V1

V2

Reverse primer MID Adaptor B

Figure 5. Fusion primers design. Adaptor sequences A and B, MID, forward and reverse primers, and
bacterial DNA template. 16S RNA variable regions V1 and V2 were amplified. Adaptor sequence A or
B bind to emPCR beads while unidirectional sequencing starts from the opposite end. MIDs serve to
tag each sample, allowing for massive parallel sequencing.
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Emulsion PCR (emPCR) and unidirectional sequencing were performed according to the
Sequencing methods manuals (Roche Life Sciences) at the Center for Applied Genetics and
Technology of the University of Connecticut (Storrs-CT). Briefly, libraries were diluted and
amplified using a Roche 454 GS titanium Small Volume emPCR kit (Lib-L) at a ratio of two
molecules of library per bead. Enriched beads were loaded in ten regions of two eight-region GS
titanium PicoTiter plates and sequenced with a GS titanium sequencing kit (XLR70) for 200
cycles on a Roche 454 GS FLX pyrosequencer. Raw image data were processed on a computer
cluster with Roche 454 data analysis processing software.
3.4.3 Processing and analysis of the bacterial sequences
3.4.3.1 Sequence pre-processing
Sequences were processed using the Mothur software [138]. Primers were removed and samples
were separated according to their MID. Sequence quality was then assessed using Pyronoise
[139] as implemented in Mothur. Next, alignment and sequence distance calculation were
conducted, and sequences clustered into operational taxonomic units (OTUs) based on a 3%
discrepancy [28]. Classification of sequences was performed using the Ribosome Database
Project (RDP) classifier [26] and the Human Oral Microbiome Database (HOMD)
(www.homd.org) and the RDP trainset as templates. OTUs were classified according to the
majority taxonomic assignments.

HOMD was used as a primary reference at the species level. When species nomenclature was not
specified by HOMD, a consensus between RDP and HOMD was sought at the genus level.
When such consensus was not reached, RDP was used as the primary reference. The terminology
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“Unclassified” plus the nearest taxonomic level at which classification was possible was
employed thereafter. For OTUs not classified at a species level, the representative (middle)
sequence of each OTU was compared via BLAST against the HOMD. This BLAST
classification was reported if results showed more than 97% similarity to a HOMD oral taxon. In
such case, the oral taxon (OT) name was reported in parentheses as part of the OTU taxonomy.
3.4.3.2 Overall data analysis
A schematic representation of the analyses conducted in this work is displayed in Figure 6.
Clinical and microbiological assessments were performed in CKD and Control patients with CP
in cross-sectional (Aim1) and longitudinal (Aim2) fashions. Clinical and non-dichotomous
demographic data were expressed as means ± standard deviation, median, and range.
Demographic dichotomous data (i.e.: gender, ethnicity, diabetes status) were presented as
percentage of subjects. Microbial data were expressed as mean percentage ± standard deviation
or percentage prevalence. Statistical significance was considered when p values were <0.05 after
adjusment for multiple comparisons, if appropriate.
Microbiome analysis
Microbiome analysis included evaluation of alpha (α-) and beta (ß-) diversity (Figure 6). OTU
prevalence was assessed by employing the appropriate statistical methods (chi-square (χ2) and
McNemar for categorical unrelated and related data, respectively); OTU abundance was
evaluated by the LEfSe algorithm [140] or via Wilcoxon Signed Rank test for non-parametric
unrelated and related data, respectively.
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Alpha diversity analysis comprised samples richness, evenness, and total diversity. Richness was
assessed by the evaluation of the number of observed OTUs. Evenness was obtained using the
Shannon evenness index, while total diversity was evaluated by the Simpson and the Shannon
indices [141-143]. Appropriate statistics for parametric and non-parametric data were employed
to assess differences in α-diversity (Aim 1: independent t-test or Mann Whitney; Aim 2: Paired
t-test or Wilcoxon Signed Ranks).

Beta diversity analysis was performed by calculating the distance between communities using
principal coordinate analysis (PCA) based on ThetaYC [144] and Jaccard similarity indices
[145], as well as Unifrac metrics [141].
Demographic and Clinical Data Analyses
Demographic, clinical, and microbial parameters were evaluated using Statistical Product and
Service Solutions software (SPSS – Chicago, IL).

For cross-sectional comparisons (Aim 1) independent sample tests were used, while appropriate
paired tests were used for longitudinal analyses, according to the nature of the data (continuous or
nominal) and its distribution. A comparison between the groups was also performed to evaluate
the changes (delta) in clinical and microbiological results. Pre-SRP values were subtracted from
post-SRP values and the outcomes were contrasted between CKD and Control subjects.
Therefore, negative values for the clinical parameters evaluated imply improvement from preSRP to post-SRP.
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CKD subjects with
CP
Before SRP
AIM2

AIM1
Clinical & demographic analyses
α-diversity
ß-diversity
Taxa relative abundance
Taxa Prevalence

Control subjects
with CP

Clinical & demographic analyses
α-diversity
ß-diversity
Taxa relative abundance
Taxa Prevalence

Before SRP
AIM2
Clinical & demographic analyses
α-diversity
ß-diversity
Taxa relative abundance
Taxa Prevalence

After SRP

After SRP
AIM2
Clinical & demographic analyses
α-diversity
ß-diversity
Taxa relative abundance
Taxa Prevalence

5. Results
5.1 Aim 1
The first aim of this thesis (Aim 1) was to compare the subgingival microbiome composition of
Control and CKD subjects with CP. Initially, we were able to enroll 17 control subjects and 15
CKD subjects. The two groups, however, were not matched in terms of demographic, medical
(diabetes) and clinical periodontal characteristics. Therefore, only 13 controls and 14 CKDs were
selected for the final analysis to achieve matching of the groups by age (p=0.55), gender
(p=0.52), ethnicity (white and non-white – hispanic and african-americans; p=0.56), and diabetes
status (p=0.06) (Table 7). Similarly, mean PD (p=0.07), mean CAL (p=0.33), BoP% (p=0.13),
and PS% (p=0.10) were comparable between Control and CKD patients. The only difference
between the two groups was in the percentage of sites with PD≥5mm (p=0.049), an indication of
disease extent, which was marginally increased in Control patients.
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Table 7. Clinical and demographic analyses of Control and CKD patients with CP. Control
subjects presented marginally increased percentage of sites with PD≥5mm (PD: pocket depth;
CAL: clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: millimeters; data are
presented as percentage of individuals or mean ± standard deviation, median, and range).
Characteristic

Control (13)

CKD (14)

Statistical test (p value)

Age

48.4±10.6
(48; 32-69)
M = 69.2%
F = 30.8%
W = 38.5%
NW = 61.5%
Y = 15.4%
N = 84.6%
3.3±0.64
(3.15; 2.4-5.0)
3.6±0.9
(3.40; 2.4-6.0)
52.0±25.0
(49; 16-100)
59.0±20.0
(62; 30-100)
21.0±15.0
(18; 4-65)

60.1±16.1
(61; 22-80)
M = 57.1%
F = 42.9%
W = 57.1%
NW = 42.9%
Y = 50.0%
N = 50.0%
3.0±0.54
(2.84; 2.4-4.3)
3.7±1.38
(3.13; 2.5-7.5)
37.0±25.0
(32; 1-89)
74.0±25.0
(82; 29-100)
13.0±12.0
(8; 3-45)

t-test (p=0.55)

(Years)

Gender
(M: male; F: female)

Ethinicity
(W: white; NW: non-white)

Diabetes status
(Y: yes; N: no)

Mean PD (mm)
Mean CAL (mm)
BoP
(% of sites)

PS
(% of sites)

PD ≥ 5mm
(% of sites)

Chi-square (p=0.52)
Chi-square (p=0.56)
Chi-square (p=0.06)
Mann Whitney (p=0.07)
Mann Whitney (p=0.33)
t-test (p=0.13)
t-test (p=0.10)
Mann Whitney (p=0.049)

Stratification of PD into 1-3mm, 4-5mm, and >5mm also depicted a marginally significant
difference in the percentage of sites with PD>5mm for the Control group (Figure 7; p=0.049). In
contrast, similar CAL distributions were seen between Control and CKD cohorts (Figure 8)
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Figure 7. Stratified pocked depth distribution. An increased percentage of sites with PD>5mm
was found in Control individuals (Mann Whitney = 1-3mm: 0.2; 4-5mm: 0.13; >5mm: 0.015).

Stratified clinical attachment levels distribution	
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Figure 8. Stratified clinical attachment levels distribution. No differences were found between
Control and CKD subjects (Mann Whitney = 1-3mm: 0.73; 4-5mm: 0.06; >5mm: 0.18).

31

Clinical analyses of sites sampled for microbiological evaluation are shown in Figure 9. There
was a trend for higher PDs in sampled sites of Controls. This difference, however, was not
statistically significant.
Clinical attachment levels of sampled sites	


Pocket depth of sampled sites	
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Figure 9. Similar PD and CAL were found in sampled sites of Control and CKD subjects
(Independent t-test = PD: 0.06; CAL: 0.74).
Subgingival plaque analysis from 13 Control and 14 CKD patients with CP rendered 874
species-level operational taxonomic units (OTUs). A comparison of CKD and Control
communities revealed no statistical differences in α-diversity (Table 8).
Table 8. α-diversity analysis depicted comparable subgingival plaque communities in Control
and CKD patients (data presented as mean ± standard deviation).
Alpha diversity analysis (Control vs CKD)
Control (13)

CKD (14)

Ind t-test (p value)

Number of observed OTUs

175.3±45.4

147.1±56.0

p=0.16

Estimated OTUs

301.5±120.6

236.4±97.8

p=0.14

Inverse Simpson

14.9±8.1

14.6±11.0

p=0.95

NP Shannon

3.4±0.6

3.2±1.0

p=0.43

Shannon evenness

0.65±0.1

0.6±0.2

p=0.60

Principal component analysis (PCA) of distance among samples based on ecology metrics that
take into account OTU proportions (ThetaYC and weighted Unifrac) revealed no differences
between CKD and Control patients (Figure 10). On the contrary, PCA based on ecology indices
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that compare samples based on OTU prevalence revealed a difference in the composition of
communities in CKD and Control groups. The CKD group seemed to present two subgroups: (i)
CKD-outliers, with 42.9% of samples clustered apart from Control samples; and (ii) CKDControl (CKD-C), which showed 57.1% of samples with similar community composition to the
Control group (Figure 11; Jaccard index p=0.023; unweighted Unifrac p=0.022).

Beta diversity analysis
ThetaYC

Weighted Unifrac
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CKD

Figure 10. ThetaYC and weighted Unifrac ß-diversity analysis. Community structure evaluation
based on relative abundance of taxa showed no difference between Control and CKD groups.
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Beta diversity analysis
Jaccard

Unweighted Unifrac
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Figure 11. Jaccard and unweighted Unifrac ß-diversity analysis. Different prevalence of taxa
was found between Control and CKD, the latter which displayed 2 subgroups (CKD-outliers in the
Jaccard plot are indicated by arrows).

Next, we compared relative abundance using LEfSe algorithm at the OTU and Genus levels.
Eight genera were more abundant in Control samples compared to only one Genus in the CKD
group (Figure 12). Fifteen OTUs were differentially represented in the Control group, while 2
OTUs were more abundant in the CKD group (Figure 13). In addition, prevalence analysis was
performed using Chi-square statistics, which displayed no differences in individual OTUs and
genera between groups.

In summary, these results show that CKD and control subjects with similar demographic and
clinical characteristics present comparable community structure. A subgroup of CKD subjects,
however, shows different community composition than Controls. No single OTU, however,
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could explain these differences in community composition as tested by prevalence analysis.
Moreover, we found a few OTUs with significantly different proportions between groups, with
most differentially represented OTUs appearing as increased in the Control group.
Relative abundance of Genera (LEfSe)

Figure 12. Genera relative abundance (LEfSe). Eight genera were differentially represented in
the Control group, while one genus was more abundant in CKD subjects.
Relative abundance of individual taxa (LEfSe)

Figure 13. Taxa relative abundance (LEfSe). Fifteen OTUs were differentially represented in the
Control group. Two OTUs were more abundant in CKD subjects.
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Our next task was to explore the factors driving the clustering separation between CKD
communities (Figure 11). Specifically, demographic, clinical, and microbiological analyses were
performed. Similar age distribution and diabetes status were found between the two CKD
subgroups, while the CKD-outlier subgroup presented more males and non-white subjects.
Periodontal clinical parameters evaluated (mean PD, mean CAL, BoP, PS, and percentage of
sites with PD≥5mm) did not show statistical differences (Table 9). Diversity comparisons
between the CKD subgroups were then performed, which showed that the CKD-outliers had
decreased diversity compared to CKD-C and Controls samples (Table 10).

Table 9. Clinical and demographic evaluation of CKD-outliers and CKD-C groups (PD: pocket
depth; CAL: clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: millimeters; data are
presented as percentage of individuals or mean ± standard deviation, median, and range).
Characteristic

CKD-outliers (6)

CKD-C (8)

Statistical test (p value)

Age
(Years)
Gender
(M: male; F: female)
Ethinicity
(W: white; NW: non-white)
Diabetes status
(Y: yes; N: no)
Mean PD (mm)

64.3±13.4
(64.5; 45-80)
M = 83.0%
F = 17.0%
W = 33.0%
NW = 67.0%
Y = 50.0%
N = 50.0%
3.0±0.7
(2.8; 2.5-4.3)
3.6±1.0
(3.1; 2.5-5.2)
40.0±28.0
(35; 11-89)
73.0±28.0
(83; 29-99)
16.0±15.0
(12; 5-45)

55.8±18.7
(59; 22-79)
M = 17.5%
F = 82.5%
W = 75.0%
NW = 25.0%
Y = 50.0%
N = 50.0%
3.0±0.5
(2.9; 2.6-4.1)
3.8±1.7
(3.0; 2.7-7.5)
29.0±20.0
(27; 1-67)
72.0±28.0
(77; 31-100)
11.0±11.0
(6; 3-36)

t-test (p=0.07)

Mean CAL (mm)
BoP
(% of sites)
PS
(% of sites)
PD ≥ 5mm
(% of sites)

Chi-square (p=0.00)
Chi-square (p=0.00)
Chi-square (p=1.00)
t-test (p=0.50)
t-test (p=0.35)
t-test (p=0.40)
t-test (p=0.89)
Mann Whitney (p=0.37)
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Table 10. Community composition comparison between CKD-outliers and CKD-C (αdiversity). Decreased diversity was found for CKD-outliers (data are presented as mean ± standard
deviation).
Alpha diversity analysis (CKD-outliers vs CKD-C)
CKD-outliers (6)

CKD-C (8)

Ind t-test (p value)

Number of observed OTUs

101.8±40.7

181.1±39.0

p=0.004

Estimated OTUs

169.0±93.6

287.1±68.3

p=0.029

Inverse Simpson

8.1±5.8

19.5±11.7

p=0.036

NP Shannon

2.5±1.2

3.7±0.5

p=0.049

Shannon evenness

0.5±0.2

0.7±0.1

p=1.00

In addition, other CKD-related factors (i.e.: antibiotics prophylaxis, diabetes status, albumin
levels, or dialysis vintage) were compared between CKD-outliers and CKD-C and no statistical
difference was found.

We also performed bivariate correlation analysis to assess the relationship between CKD-related
variables and microbiome diversity. Pearson statistics revealed a negative correlation between
dialysis vintage (years in dialysis) and diversity as measured by the Simpson diversity index
(Table 11; r2=-0.65, p=0.03).
Table 11. Comparison of CKD-related data between CKD outliers and CKD-C and correlations
with diversity parameters. Increased time in dialysis was correlated with decreased community
diversity (CKD-related data are presented as percentage of individuals or mean ± standard deviation, median, and
range).
Comparisons of CKD-related variables

Dialysis vintage
(Years)
Antibiotic prophylaxis
(Y: yes; N: no)
Albumin levels
(g/dL)

CKD-outliers
(6)

CKD-C
(8)

Statistics
(p value)

Pearson correlations

4.4±1.5
(4;3-7)
Y = 67%
N = 33%
4.2±0.3
(4.3;3.7-4.4)

3.7±2.2
(4.5;1-6)
Y = 25%
N = 75%
3.8±0.4
(4;3-4.3)

Mann Whitney
(p=0.92)
Chi-square
(p=0.28)
Mann Whitney
(p=0.07)

r2=-0.65; p=0.03
(Correlated to Inverse Simpson)
Non-significant
Non-significant
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In summary, in this aim we showed that in matched CKD and Control subjects with CP, CKD is
not associated with a specific microbial profile. The communities of CKD subjects, however,
appeared to be highly heterogeneous with a subgroup showing decreased diversity.

5.2 Aim 2
The second aim of this thesis (Aim 2) was to evaluate the clinical and microbiological response
to non-surgical periodontal treatment in Control and CKD subjects with CP. Here we included
all recruited Controls (n=15) and all recruited CKD subjects (n=6) that completed initial
periodontal therapy. These two cohorts were compared in terms of their demographic, clinical,
and microbiological characteristics before and after scaling and root planning (SRP).

5.2.1 Baseline evaluation
Since the two groups differed from those described in Aim 1, we first performed a crosssectional comparison of their baseline characteristics. At pre-SRP, age was statistically different
between the groups. CKD subjects were older when compared to Control individuals (Table 12;
p=0.013). No differences, however, were found for gender (p=0.52), ethnicity (p=0.56), diabetes
status (p=0.06), mean PD (p=0.70), mean CAL (p=0.80), BoP% (p=0.90), PS% (p=0.92), and
percentage of sites with PD≥5mm (p=0.94).
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Table 12. Clinical and demographic analyses of Control and CKD patients with CP before SRP.
CKD subjects presented increased age (PD: pocket depth; CAL: clinical attachment level; BoP:
bleeding on probing; PS: plaque score; mm: millimeters; data are presented as percentage of individuals
or mean ± standard deviation, median, and range).
Characteristic

Control (15)

CKD (6)

Statistical test (p value)

Age

50.0±10.0
(49; 32-69)
M = 66.7%
F = 32.3%
W = 46.7%
NW = 53.3%
Y = 20.0%
N = 80.0%
3.45±0.95
(3.3; 2.4-6.0)
3.7±1.1
(3.5; 2.4-6.0)
51.0±28.0
(49; 16-100)
59.0±19.0
(62; 30-100)
12.0±15.0
(7; 1-56)

70.0±13.0
(76; 44-79)
M = 66.7%
F = 32.3%
W = 83.3%
NW = 16.7%
Y = 66.7%
N = 32.3%
3.3±0.7
(3.0; 2.8-4.3)
4.3±1.8
(3.7; 3.0-7.5)
49.0±26.0
(46; 16-89)
74.0±24.0
(83; 35-99)
12.0±13.0
(6; 1-36)

Mann Whitney (p=0.013)

(Years)

Gender
(M: male; F: female)

Ethnicity
(W: white; NW: non-white)

Diabetes status
(Y: yes; N: no)

Mean PD (mm)
Mean CAL (mm)
BoP
(% of sites)

PS
(% of sites)

PD ≥ 5mm
(% of sites)

Chi-square (p=0.52)
Chi-square (p=0.56)
Chi-square (p=0.06)
Mann Whitney (p=0.70)
Mann Whitney (p=0.80)
t-test (p=0.90)
t-test (p=0.92)
Mann Whitney (p=0.94)

Stratification of PD and CAL into 1-3mm, 4-5mm, and >5mm also showed no differences
between the groups (PD: Figure 14; CAL: Figure 15). Figure 16 depicts the analysis of sites
sampled for microbiological evaluation. Comparable PD and CAL were found for sampled sites
of Control and CKD subjects.

39
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Figure 14. Stratified pocket depth distribution. No differences were found between Control and
CKD subjects.
Stratified clinical attachment levels (pre-SRP)	
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Figure 15. Stratified clinical attachment levels distribution. No differences were found between
Control and CKD subjects.
This pre-SRP analysis indicated that CKD and Control groups presented similar clinical and
demographic characteristics, except for the increased age values found for CKD subjects.
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Figure 16. Similar PD and CAL were found in sampled sites of Control and CKD subjects.
Subgingival plaque analysis from 15 Control and 6 CKD patients with CP rendered 725 specieslevel operational taxonomic units (OTUs). Similar to Aim 1, no α-diversity differences were
found between CKD and Control communities (Table 13).

Table 13. α-diversity analysis displayed similar subgingival plaque communities in Aim 2
Control and CKD patients (data are presented as mean ± standard deviation).
Alpha diversity analysis (Control vs CKD pre-SRP)
Number of observed OTUs
Estimated OTUs
Inverse Simpson
NP Shannon
Shannon evenness

Control (15)
170.5±47.6
265.1±83.6
15.2±8.6
3.4±0.7
0.65±0.1

CKD (6)
142.0±45.0
211.6±57.0
16.9±15.0
3.3±0.8
0.7±0.1

Ind t-test (p value)
p=0.23
p=0.11
p=0.80
p=0.82
p=0.90

Distance metric analyses of OTU proportions (ThetaYC and Weighted Unifrac) and prevalence
(Jaccard and Unweighted Unifrac) showed no differences between CKD and Control subjects
(Figure 17).
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Figure 17. Community structure evaluation based on relative abundance (ThetaYC; Weighted
Unifrac) and prevalence (Jaccard; Unweighted Unifrac) of taxa showed no difference between
Control and CKD groups.
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Relative abundance and prevalence of taxa before SRP were also evaluated. LEfSe analysis at
the OTU level showed an increased relative abundance of fourteen OTUs in the Control samples
compared to two OTUs in the CKD samples (Figure 18). At the Genus level, five Genera were
more abundant in the Control group compared to only one Genus in CKD subjects (Figure 19).
Finally, prevalence statistics using Chi-square displayed no differences between the groups.
Relative abundance of individual taxa (LEfSe)

Figure 18. Taxa relative abundance (LEfSe). Fourteen OTUs were differentially represented in
the Control group. Two OTUs were more abundant in CKD subjects.
Relative abundance of Genera (LEfSe)

Figure 19. Genera relative abundance (LEfSe). Five genera were differentially represented in the
Control group, while one Genus was more abundant in CKD subjects.
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The outcomes for the pre-SRP samples of the Aim2 cohorts revealed compatible values for
clinical and demographic characteristics. Additionally, plaque sample analyses showed similar
alpha and beta diversity.
5.2.2 Longitudinal evaluation – Control group
Next, separate longitudinal analyses were conducted for CKD and Control groups. The clinical
outcomes of SRP in the Control are shown in Table 14. Significant improvements were evident
in mean PD, mean CAL, percentage of sites with BoP and PS.

Table 14. Clinical analysis of Control patients from pre-SRP to post-SRP. Decreased post-SRP
values were found for mean PD and CAL, as well as percentage of sites with BoP and PS. (PD:
pocket depth; CAL: clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm:
millimeters; data are presented as mean ± standard deviation, median, and range).
Characteristic

Pre-SRP (15)

Post-SRP (15)

Statistical test (p value)

Mean PD (mm)

3.45±0.93
(3.3; 2.4-6.0)
3.7±1.0
(3.5; 2.4-6.0)
51.0±27.0
(49; 16-100)
59.0±19.0
(62; 30-100)

2.8±0.4
(2.7; 2.3-3.7)
3.0±0.5
(3.0; 2.4-4.0)
29.0±15.0
(26; 9-65)
35.0±16.0
(31; 8-73)

Wilcoxon Signed Ranks
(p=0.003)
Wilcoxon Signed Ranks
(p=0.003)
Paired t-test
(p=0.004)
Wilcoxon Signed Ranks
(p=0.001)

Mean CAL (mm)
BoP
(% of sites)

PS
(% of sites)

Stratification of PD and CAL into 1-3mm, 4-5mm, and >5mm also showed significant
improvement from pre-SRP to post-SRP (PD: Figure 20; CAL: Figure 21). Specifically,
increased percentage of sites with PD/CAL 1-3mm and decreased percentage of sites with
PD/CAL 4-5 and >5mm were found at post-SRP. Figure 22 depicts the analysis of sites sampled
for microbiological evaluation. At post-SRP, decreased PD and CAL were evident in sampled
sites of Control subjects.
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Figure 20. Stratified pocket depth distribution. Decreased PD of 4-5mm and >5mm were found
at post-SRP.

Stratified clinical attachment levels (Control)	
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Figure 21. Stratified clinical attachment level distribution. Decreased CAL of 4-5mm and >5mm
were found at post-SRP.
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Figure 22. Pocket depth and clinical attachment levels of sampled sites. At post-SRP, decreased
PD and CAL were evident.

Microbial analyses of subgingival plaque in 15 Control patients before and after SRP rendered
886 species-level OTUs. Alpha-diversity evaluation displayed similar community compositions
at pre-SRP and post-SRP (Table 15).

Likewise, ß-diversity evaluation of OTU proportions (ThetaYC and Weighted Unifrac) and
prevalence (Jaccard and Unweighted Unifrac) showed no specific clustering of samples
according to treatment status (Figure 23).
Table 15. α-diversity analysis displayed similar subgingival plaque communities in Control
samples before and after SRP (data are presented as mean ± standard deviation).
Alpha diversity analysis (Control)
Pre-SRP (15)

Post-SRP (15)

Statistics (p value)

Number of observed OTUs

170.0±50.9

172.0±47.1

Paired t-test (p=0.9)

Estimated OTUs

275.5±114.8

274.8±84.4

Wilcoxon Signed Ranks (p=0.99)

Inverse Simpson

15.2±8.4

17.4±8.0

Paired t-test (p=0.45)

NP Shannon

3.4±0.7

3.5±0.6

Wilcoxon Signed Ranks (p=0.6)

Shannon evenness

0.65±0.1

0.7±0.1

Wilcoxon Signed Ranks (p=0.42)
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Figure 23. Community structure and composition evaluation based on relative abundance
(ThetaYC; Weighted Unifrac) and prevalence (Jaccard; Unweighted Unifrac) of taxa showed no
differences between pre- and post-SRP in Control subjects.

Differences in relative abundance of individual taxa between pre- and post-SRP were then
evaluated by Wilcoxon Signed Ranks test. While twenty-one OTUs were statistically more
abundant at pre-SRP, fifteen taxa showed increased representation at post-SRP (Table 16). At the
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genus level, twelve genera showed increased abundance before SRP, while six were more
abundant after SRP (Table 17). Finally, one Phylum had increased representation at pre-SRP and
two were increased post-SRP (Table 18).
Table 16. Differentially represented taxa in Control samples at pre- and post-SRP. Twenty-one
and fifteen OTUs were abundant at pre-SRP and post-SRP, respectively.
Relative abundance of OTUs (Control)
Increased in Pre-SRP
Wilcoxon
Increased in Post-SRP
Unclassified Peptostreptococcaceae [11]
(P. [11] [G4] sp. OT369)
Parvimonas micra

p = 0.001

Wilcoxon
p = 0.008

p = 0.007

Unclassified Lachnospiraceae [14]
(Oribacterium sp. OT372)
Streptococcus sp. OT071

Prevotella intermedia (OT643)

p = 0.008

Capnocytophaga leadbetteri

p = 0.018

Eubacterium [11] [G6] nodatum

p = 0.008

Prevotella saccharolytica

P = 0.02

Tannerella forsythia

p = 0.01

Granulicatella adjacens

p = 0.021

Desulfobulbus sp. OT041

p = 0.014

Prevotella oulorum

p = 0.029

Filifactor alocis

p = 0.016

Leptotrichia sp. OT498

p = 0.031

Unclassified Veillonellacea
(V. [G1] sp. OT145)
Treponema maltophilum

p = 0.016

Abiotrophia defectiva

p = 0.031

p = 0.026

Rothia aeria

p = 0.035

Fusobacterium sp.
(F. nucleatum ss. vincentii OT200)
Prevotella intermedia

p = 0.003

Prevotella nigrescens

p = 0.035

p = 0.031

Actinomyces sp. OT169

p = 0.038

Treponema sp. OT257

p = 0.031

TM7 [G1] sp. OT348

p = 0.039

Fusobacterium nucleatum ss. vincentii

p = 0.031

p = 0.039

Porphyromonas gingivalis

p = 0.031

Selenomonas sp.
(S. flueggei OT125)
Actinomyces sp. (OT170)

Dialister pneumosintes

p = 0.033

Prevotella tannerae

p = 0.047

Treponema socranskii

p = 0.04

Synergistetes [G3] sp. OT363

p = 0.042

Prevotella sp. OT304

p = 0.047

Catonella morbi

p = 0.047

p = 0.009

p = 0.042
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Table 17. Differentially represented Genera in Control samples at pre- and post-SRP. Twelve
and six Genera were abundant at pre-SRP and post-SRP, respectively.
Relative abundance of Genera (Control)
Increased in Pre-SRP
Wilcoxon Increased in Post-SRP

Wilcoxon

Peptostreptococcaceae [11] [G4]

p = 0.002

Actinomyces

p = 0.008

Chloroflexi [G1]

p = 0.004

Leptotrichia

p = 0.015

Tannerella

p = 0.005

Oribacterium

p = 0.015

Eubacterium [11] [G6]

p = 0.006

Selenomonas

P = 0.025

Desulfobulbus

p = 0.008

Eikenella

p = 0.028

Mycoplasma

p = 0.008

TM7 [G1]

p = 0.03

Unclassified Burkholderiales

p = 0.016

Johnsonella

p = 0.016

Eubacterium [11] [G3]

p = 0.018

Unclassified Fusobacteriaceae

p = 0.025

Pseudoramibacter

p = 0.036

Desulfovibrio

p = 0.047

Table 18. Differentially represented Phyla in Control samples at pre- and post-SRP. One and two
Phyla were abundant at pre-SRP and post-SRP, respectively.
Relative abundance of Phyla (Control)
Increased in Pre-SRP

Wilcoxon

Increased in Post-SRP

Wilcoxon

Chloroflexi

p = 0.015

Actinobacteria

p = 0.035

TM7

p = 0.008

Comparisons between the pre- and post-SRP prevalence of taxa, Genera, and Phyla were
conducted using McNemar statistics (Table 19). Results showed increased prevalence of seven
OTUs in pre-SRP and four OTUs in post-SRP. Furthermore, four Genera and one Phylum were
more prevalent at pre-SRP only (Tables 20 and 21).
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Table 19. Prevalence of taxa in Control samples at pre- versus post-SRP. Seven and four OTUs
were more prevalent at pre-SRP and post-SRP, respectively.
Prevalence of OTUs (Control)
Prevalent at pre-SRP
McNemar
Prevalent at Post-SRP

McNemar

Mogibacterium timidum

p = 0.016

Capnocytophaga leadbetteri

p = 0.016

Chloroflexi [G1] sp. OT439

p = 0.016

Granulicatella adjacens

p = 0.016

Parvimonas micra

p = 0.031

Capnocytophaga granulosa

p = 0.031

Prevotella intermedia

p = 0.031

Neisseria sp. (N. sicca OT764)

P = 0.031

Porphyromonas gingivalis

p = 0.031

Unclassified Peptostreptococcaceae [11] (P.
[11][G4] sp. OT369)
Prevotella buccae

p = 0.039
p = 0.039

Table 20. Prevalence of Genera in Control samples at pre- versus post-SRP. Four Genera were
more prevalent at pre-SRP.
Prevalence of OTUs (Control)
Prevalent at pre-SRP

McNemar

Chloroflexi [G1]

p = 0.008

Unclassified Fusobacteriaceae

p = 0.031

Eubacterium [11] [G3]

p = 0.039

Peptostreptococcaceae [11] [G4]

p = 0.039

Table 21. Prevalence of Phyla in Control samples at pre- versus post-SRP. Only one Phylum
was more prevalent at pre-SRP.
Prevalence of OTUs (Control)
Prevalent at pre-SRP
McNemar
Chloroflexi

p = 0.008

Figure 24 depicts the twenty most abundant OTUs in Control at pre-SRP (blue) and post-SRP
(red). These graphs show that although some of the levels of periodontitis-associated taxa
changed in response to treatment, 15 out of the 20 most abundant OTUs at baseline remained in
the top 20 post-therapy. These surprising results show that although we observed expected trends
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for a decrease of disease-associated species and an increase in health-associated species postSRP, initial therapy did not dramatically change subgingival communities despite significant
improvements in clinical parameters.

Figure 24. Twenty most abundant OTUs in Control subjects at pre-SRP (blue) and post-SRP
(red). Fifteen of the 20 most abundant taxa at pre-SRP were still present at post-SRP.
5.2.3 Longitudinal evaluation – CKD group
The results of non-surgical periodontal therapy in CKD patients are depicted in Table 22. All
parameters showed a trend to decrease after SRP, however, only CAL and the percentage of sites
with BoP were statistically significant. Conversely, mean PD and the percentage of sites with PS
showed no statistically significant difference from pre-SRP to post-SRP (Table 22).
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Table 22. Clinical analysis of CKD patients from pre-SRP to post-SRP. Decreased post-SRP
values were found only for mean CAL and percentage of sites with BoP. (PD: pocket depth; CAL:
clinical attachment level; BoP: bleeding on probing; PS: plaque score; mm: millimeters; data are
presented as mean ± standard deviation, median, and range).
Characteristic

Pre-SRP (6)

Post-SRP (6)

Statistical test (p value)

Mean PD (mm)

3.34±068
(3.0; 2.8-4.3)
4.35±1.7
(3.8; 3.0-7.5)
49.0±26.0
(46; 16-89)
76.0±24.0
(83; 35-99)

2.7±0.6
(2.7; 1.9-3.7)
3.6±1.6
(2.9; 1.9-6.2)
11.0±15.0
(6; 0-39)
45.0±26.0
(38; 17-93)

Paired t-test
(p=0.09)
Paired t-test
(p=0.017)
Wilcoxon Signed Ranks
(p=0.031)
Wilcoxon Signed Ranks
(p=0.563)

Mean CAL (mm)
BoP
(% of sites)

PS
(% of sites)

The percentages of sites with PD of 1-3mm, 4-5mm, and >5mm were not statistically different
from before to after non-surgical periodontal therapy, although similar trends as those shown for
the Control group were observed. In contrast, stratification of CAL sites into 1-3mm, 4-5mm,
and >5mm showed significant improvement from pre-SRP to post-SRP for CALs of 1-3mm and
>5mm (PD: Figure 25; CAL: Figure 26). Evaluation of sites sampled for microbiological
analysis showed decreased PD and CAL at post-SRP (Figure 27).
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Figure 25. Stratified pocket depth distribution. No differences were found in the CKD group
from pre-SRP to post-SRP.
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Clinical attachment levels (CKD)	
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Figure 26. Stratified clinical attachment level distribution. Increased CAL of 1-3mm and
decreased CAL of >5mm were found at post-SRP.
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Figure 27. Pocket depth and clinical attachment levels of sampled sites. At post-SRP, decreased
PD and CAL were evident.
Subgingival plaque samples collected from 6 CKD subjects rendered 537 species-level OTUs. In
similar fashion to the Control group, alpha-diversity evaluation showed no differences pre- and
post-SRP (Table 23).
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Table 23. α-diversity analysis revealed no differences in CKD samples before and after SRP
(data are presented as mean ± standard deviation).
Alpha diversity analysis (CKD)
Pre-SRP (6) Post-SRP (6)

Statistical (p value)

Number of observed OTUs

135.3±45.2

161.2±42.7

Paired t-test (p=0.22)

Estimated OTUs

186.9±52.4

237.7±53.0

Paired t-test (p=0.11)

Inverse Simpson

17.0±15.2

22.6±12.2

Paired t-test (p=0.34)

NP Shannon

3.3±0.7

3.7±0.4

Paired t-test (p=0.1)

Shannon evenness

0.66±0.1

0.7±0.07

Paired t-test (p=0.48)

Likewise, ß-diversity evaluation of distance among samples based on OTU proportions
(ThetaYC and Weighted Unifrac) and prevalence (Jaccard and Unweighted Unifrac) showed no
tendency for samples to cluster before and after non-surgical treatment groups (Figure 28).
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Figure 28. Analyses of community structure (ThetaYC; Weighted Unifrac) and prevalence
(Jaccard; Unweighted Unifrac) of taxa showed no differences between pre- and post-SRP in
CKD subjects.
Comparative assessment of relative abundance between pre- and post-SRP displayed five OTUs
and two Genera, which were more abundant at post-SRP (Table 24 and Table 25). At the Phylum
level, there were no differences in abundance at pre- and post-SRP. Lastly, no significant
differences were found for prevalence analyses at all levels for CKD subjects before and after
non-surgical therapy.
Table 24. Relative abundance of OTUs in CKD samples at pre- versus post-SRP. Five taxa were
more abundant at post-SRP.
Relative abundance of OTUs (CKD)
Increased post-SRP

Wilcoxon

Unclassified Fusobacterium
(F. nucleatum ss. animalis OT420)
Unclassified Prevotella (OT317)
Campylobacter gracilis
Unclassified Porphyromonas (OT279)
Solobacterium moorei

p = 0.031
p = 0.031
p = 0.031
p = 0.031
p = 0.031
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Table 25. Relative abundance of Genera in CKD samples at pre- versus post-SRP. Two taxa
were more abundant at post-SRP.
Relative abundance of OTUs
(CKD)
Increased
post-SRP
Wilcoxon
Gemella

p = 0.031

Solobacterium

p = 0.031

Figure 29 depicts the twenty most abundant OTUs in CKD at pre-SRP (blue) and post-SRP (red).
Similar to Controls, 11 out of the top 20 OTUs in pre-SRP samples were still part of the top 20
OTUs post-SRP, showing that the communities do not change dramatically. While some
pathogenic species that numerically dominated the pre-SRP communities, such as P. gingivalis
and T. forsythia, decreased in abundance after therapy, it is clear though that the CKD post-SRP
communities became dominated by a great variety of Prevotella spp. In summary, the results of
the longitudinal evaluation in CKD patients revealed modest clinical outcomes and modest, if not
adverse, changes in microbiological profiles after non-surgical therapy in CKD subjects.
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Figure 29. Twenty most abundant OTUs in CKD subjects at pre-SRP (blue) and post-SRP (red).
5.2.4 Comparison of magnitude of clinical and microbiological changes pre- to post-Scaling
and Root Planing (SRP) in CKDs and controls
To quantitatively measure the response to therapy in the two groups, we compared the magnitude
of the changes in clinical and microbiological parameters from pre-SRP to post-SRP (delta).
Comparisons of clinical responses are shown in Table 29. No differences were found in the
deltas of PD, CAL, sampled sites for microbial analyses, as well as percentage of sites with BoP
and PS.
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Table 29. Clinical analysis of the delta (from pre-SRP to post-SRP) between CKD and Control
patients. No differences in the change of clinical parameters from before to after SRP were found
between the groups. (PD: pocket depth; CAL: clinical attachment level; BoP: bleeding on probing; PS:
plaque score; mm: millimeters; data are presented as mean ± standard deviation, median, and range;
negative numbers mean improvement from pre- to post-SRP).
Characteristic

Delta (Control)

Delta (CKD)

Statistical test (p value)

PD 1-3mm (% of sites)

20±17
(16; 2.0-68)
-9.0±9.0
(-10; -33-7)
-11.0±13.0
(-5; -49-0)
18.0±17.0
(17.0;-3.0-66.0)
-5.0±8.0
(-6.0;-18.0-11.0)
-13.0±15.0
(-7.0;-51.0-2.0)
-23.0±25.0
(-17; -73-11)
-24±21.0
(-29; -69-5)
-2.7±1.1
[-3.0;-4.0-(-0.5)]
-2.8±1.4
[-3.5;-5.0-(-0.5)]

22.0±18.0
(19.0; 0-54)
-14.0±13.0
(-13.0; -35.0-2.0)
-6.0±7.0
(-2.0;-19-0)
18.0±11.0
(18.0;3.0-37.0)
-9.0±12.0
(-15.0;-20-8.0)
-9.0±9.0
(-5.0;-22.0-0.0)
-22.0±19.0
[-22.0; -50.0-(-2.0)]
-32.0±30.0
(-32.0; -82.0-0.0)
-3.3±1.1
[-3.3;-5.0-(-2.0)]
-3.75±1.3
[-4.0;-5.0-(-2.0)]

Mann Whitney
(p=0.44)
Mann Whitney
(p=0.56)
Mann Whitney
(p=0.11)
Mann Whitney
(p=1.0)
Mann Whitney
(p=0.185)
Mann Whitney
(p=0.12)
Ind t-test (p=0.95)

PD 4-5mm (% of sites)
PD > 5mm (% of sites)
CAL 1-3mm (% of sites)
CAL 4-5mm (% of sites)
CAL >5mm (% of sites)
BoP (%)
PS (%)
Sampled PD (mm)
Sampled CAL (mm)

Ind t-test (p=0.54)
Ind t-test (p=0.25)
Mann Whitney
(p=0.12)

To measure the changes in whole community composition and structure pre to post-SRP, we
calculated the distance in paired samples with different ß-diversity metrics. The paired distances
from pre- to post-SRP in CKD and Control samples are shown in Figure 30. Results showed no
difference in the distances from pre- to post-SRP related to community structure metrics
(ThetaYC and Weighted Unifrac) or community composition

(Jaccard and Unweighted

Unifrac).
The above-described outcomes suggested that both CKD and control subjects responded in a
similar manner to SRP as assessed by both clinical and microbiological parameters. However,
we also measured specific changes in the relative abundance of OTUs pre to post-SRP to
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evaluate if similar trends were observed between CKDs and controls. For this analysis, we
calculated the magnitude of change in the top 50 most abundant OTUs at baseline (calculated
after averaging relative abundance values in all subjects). Figure 31 shows that only a few OTUs
show a tendency to decrease post-SRP in both groups. Interestingly, these were the recognized
pathogens P. gingivalis and T. forsythia. Although not statisitically significant, the magnitude of
the change in these two pathogens was greater in controls than in CKDs. Surprisingly, we also
observed that the majority of the most abundant OTUs did not change in the same direction in
CKDs and controls. While most of the top OTUs at baseline decreased in abundance after SRP in
controls, there was a trend towards an increase in their abundance in the CKD group. Of notice
are a wide variety of OTUs from the genera Prevotella and Treponema, clearly associated with
disease [38, 39], which did not decrease in CKDs in response to treatment. These results
suggested that the moderate clinical outcomes observed in CKD subjects after SRP could be
linked to a lack of resolution of the infection burden by initial periodontal therapy.

Distance from pre to postSRP	


Beta diversity distance	

1	
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Figure 30. Comparison of the beta-diversity distances from pre- to post-SRP between CKD and
Control subjects. There was no statistical difference between the groups in terms of the changes
in beta diversity from pre- to post-SRP.
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Figure 31. Percentage change in the abundance of the top 50 OTUs from pre- to post-SRP. Decreased abundance of P. gingivalis and T.
forsythia in Control samples. Increased abundance of Treponema and Prevotella in CKD subjects. (red asterisks: statistical difference at p<0.05 using
Mann Whitney or Independent t-test)
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6. Discussion
Subgingival plaque in healthy and periodontitis patients has been extensively investigated. While
initial studies used conventional culture techniques, recent works were based on bacterial rRNA
gene amplification techniques [5-7, 19, 30]. The latter methods offer the ability to costeffectively process microbial 16S ribosomal RNA sequences and are of utmost importance for a
detailed characterization of the complex biofilm millieu [17-19, 31, 146]. Moreover,
deconvoluting bacterial biofilm composition may contribute to the understanding of periodontal
diseases and their association with systemic illnesses [147].

Increased evidence of the link between CP and systemic diseases is emerging. Specifically,
elevated CP prevalence has been shown in CKD patients [117-119, 148, 149]. However, there is
a gap in the literature in regards to studies that employ advanced molecular methods to evaluate
the microbiome profile of CKD patients with CP, despite the biological plausibility of an
increased uremic state as a modifier of the subgingival microbiome. Furthermore, scientific
evidence on the effectiveness of non-surgical periodontal therapy in these patients is limited
[113, 121, 135].

In this study, we conducted cross-sectional and longitudinal evaluations of the clinical and
microbiological outcomes of SRP in CP patients with and without CKD. Subgingival plaque was
collected from the two deepest sites in two different quadrants of the subjects in order to gather
data from periodontally affected niches. DNA was isolated and the V1-V2 hypervariable regions
of the 16S rRNA gene were analyzed using pyrosequencing. Our DNA isolation protocol
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included the incubation of plaque samples in proteinase K. This strategy not only aimed at
inactivating nucleases, but also at digesting the thick layer of peptidoglycans in the Grampositive bacterial wall [150]. Thus, isolation of DNA material from both Gram-positive and
Gram-negative was possible. Other studies, however, lacked this step and may have
underestimated the Gram-positive DNA composition in their samples [17, 18, 31].

Our molecular analysis of the bacterial 16S rRNA gene was aimed at increased sensitivity to
uncultivable bacteria, which have been reported to encompass 40% of the subgingival microbial
consortia [19]. Currently, only two studies have used global-scale approaches to compare the
subgingival microbiome of healthy and periodontitis patients [39, 151]. These studies helped us
define the microorganisms associated with health and disease in our samples. This prior
knowledge was useful to evaluate the differences in communities in CKDs and controls.
Comparison of our results with those of these two studies also validated our methods. For
instance, Griffen et al. (2011) sampled plaque from 29 healthy and 29 CP patients (deep and
shallow pockets), whereas Abusleme et al. (2013) compared the microbiomes of bleeding and
non-bledding sites in 22 CP versus 10 healthy subjects. The total number of OTUs described by
our work (n=874; 27 patients) slightly surpasses the ones reported by Abusleme et al. (2013)
(n=750; 32 patients), a study that also used a 97% cutoff for OTU definitions but sampled
shallower sites than the current study, and those reported by Griffen et al. (2011) (n=596; 58
patients), a phylotype-based study. Our α-diversity measures, however, are similar to the ones
reported by Griffen et al. (2011). Specifically, comparable number of OTUs/phylotypes per
patient and non-parametric (NP) Shannon index values were evident (Araújo et al. - Obs/OTUs:
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175.0, NP Shannon: 3.4; Griffen et al. - Obs/OTUs: 160.0, NP Shannon: 3.8). However, while
NP Shannon and Shannon evenness indices were equivalent between Abusleme et al. (2013) and
this study (Araújo et al. - NP Shannon: 3.4, Evenness: 0.65; Abusleme et al. - NP Shannon: 3.2,
Evenness: 0.65), the numbers of observed and estimated OTUs per sample, indicating richness,
were drastically different (Araújo et al. – Obs/OTUs: 175.0, Estimated/OTUs: 301.5; Abusleme
et al. - Obs/OTUs: 85.0, Estimated/OTUs: 140.0). The differences in the observed and estimated
OTUs may be due to the increased pocket depth of sites sampled by our study (PD≥6mm)
compared to Abusleme et al. (2013) (PD=5mm), since increased disease severity has been
correlated with increased diversity [39]. In addition, the reduced number of total OTUs reported
by Griffen et al. (2011) could be derived from their sampling technique (i.e. paperpoints), which
falls short in collecting the biofilm core and may have underestimated the number of subgingival
phylotypes.

In general, a trend to similar microbiome profiles was noticed between periodontitis samples in
our work and the studies described above. In fact, all three studies corroborate the findings
described by Socranski et al. (1998), where elevated proportions and high prevalence of P.
gingivalis, T. forsythia, and T. denticola characterize disease. It was interesting to observe
however, that our periodontitis communities were dominated by P. gingivalis, with an average
relative abundance in controls and CKDs of 10.2%, while Abusleme et al. (2013) found that P.
gingivalis was present at less than 2% abundance in periodontitis. These differences could again
be due to the fact that we sampled deeper sites than Abusleme et al. (2013), and the abundance
of P. gingivalis appears to directly correlate to pocket depth [3]. In addition, F. alocis also
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appears to be abundant in communities in our work and in periodontitis communities in the
reports of Abusleme et al. (2013) and Griffen et al. (2011). This Gram-positive rod has been
commonly found in sites with periodontal destruction [17, 18, 31, 152]. Conversely, Prevotella
was clearly associated with disease in the report of Griffen et al. (2011) and appears to be an
abundant genus in our study, whereas Abusleme et al. (2013) described sequences related to this
genus to be present in low prevalence and abundance and unchanged in health and disease. As
suggested by the latter authors, these differences may result from geographic variability (Griffen
et al. and Araújo et al.: USA; Abusleme et al.: Chile) and/or discrepant depths of sampled sites
for microbial analysis. Our sampling strategy may have thus contributed to the increased
proportions of Prevotella observed [153]. Other uncultivable organisms such as Treponema spp.,
Synergistetes spp., Desulfobulbus spp. and Bacteroidetes spp., associated with periodontitis in
reports of Griffen et al. (2011) and Abusleme et al. (2013) also appeared as abundant community
members in our samples. Moreover, species not particularly associated with health or disease
[153] but abundant members of subgingival communities such as Fusobacterium nucleatum or
Corynebacterium matruchottii were also prominent in our samples. Interestingly, healthassociated species such as Rothia and Actinomyces were also present as reported by Abusleme et
al. (2013). Overall, these results show that our analysis of the subgingival microbiome in
periodontitis was for the most part consistent with previous reports.

6.1 Periodontitis in CKD subjects is not associated with a unique subgingival microbiome
profile
The first objective of this work was to compare the microbiome of CP subjects with and without
CKD. To this end, subjects with periodontitis were recruited from the Periodontology Clinic at
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the University of Connecticut Health Center and from various dialysis units. Clinical and
microbiological analyses were initially performed in all CKD and Control enrolled subjects.
These initial cohorts, however, did not present matched periodontal parameters, with increased
disease extent in the control group. Interestingly, despite the reports on the increased CP
prevalence in CKD patients, studies that have compared the severity of CP in CKD and nonCKD cohorts have shown no difference in PD and CAL between these groups [114, 116, 117].
These studies, however, have not been conducted in large populations and therefore it is not clear
what are the differences in disease severity in CKD and non-CKD individuals. One can speculate
that despite increased prevalence of CP in CKD subjects due to a different infection burden or
perhaps different access to care, a decreased severity in the presentation of CP would be found in
CKD patients due to their deficient immune capabilities, since a great portion of the periodontal
breakdown in CP is a result of the exacerbated host response [42, 43]. Alternatively, the
increased CP severity and extent observed in the initial cohorts in this study may be have
resulted from differences in recruitment strategy between groups. While CKD patients were
screened from the general dialysis population and are expected to show a wide range of disease
severity, patients seen at the Periodontics Graduate Clinic commonly present with advanced
(moderate to severe) disease. Periodontics Graduate Clinic patients have already been
preselected by the referring general practitioners based on their disease severity (mild
periodontitis is treated by general dentists). Due to the differences observed and to answer the
main question in Aim 1, we decided to exclude some patients from the two cohorts to obtain
populations matched in terms of demographic, medical and periodontal clinical characteristics.
Our final cohorts used in Aim 1 analyses were thus matched except for the percentage of sites
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with PD≥5mm, which was marginally increased in the Control group, indicating a slightly
greater disease extent in Controls.

Recent reports on the microbiome of healthy and periodontally affected patients have associated
periodontal destruction with increased microbial diversity [31, 38, 39]. Thus, it is plausible to
expect elevated diversity values in Control samples as a result of the slightly increased disease
severity. In effect, such a trend was observed but differences were not statistically significant.
Thus, CKD status does not seem to affect alpha-diversity and the tendency observed may have
been a reflection of a slight difference in disease presentation between groups.

Principal component analysis by ThetaYC and weighted Unifrac showed no clustering of
samples according to CKD status. This result indicates that CKD does not significantly affect the
global microbial profile of periodontitis-associated subgingival biofilms. However, comparison
of proportions of individual taxa between groups showed a small proportion of taxa as
differentially represented. Most of these were over-represented in the control group. These
differences could potentially be explained by the slightly higher disease severity of controls, with
slightly higher microbiome diversity. Some of the taxa increased in controls were indeed
periodontitis-associated (i.e.: P. intermedia; F. alocis). However some of them could also be
considered comensal flora (i.e.: Streptococcus mitis). It is thus not clear if these small differences
are due to the marginal clinical difference between the Control and CKD cohorts (p=0.049) or
due to CKD status. It is also possible that these small changes are due to error derived from the
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large number of comparisons conducted. Although adjustment for multiple comparisons is part
of the LefSe algorithm, no statistical method decreases false positives completely.

On the contrary, comparisons of communities based on ß-diversity metrics (PCA) that take only
into account OTU prevalence (Jaccard and unweighted Unifrac) revealed composition
discrepancies between CKD and Control communities. These differences seemed to derive from
the evident heterogeneity found within the CKD group, which presented two subsets: (i) CKDoutliers (clustered away from Control samples) and (ii) CKD-Control (CKD-C). Prevalence
analysis, however, showed no differentially represented OTUs to explain the distance between
the Control and CKD cohorts or between the CKD subsets. The divergence between the Chisquare and the ß-diversity prevalence analyses may also be a consequence of the prominent
heterogeneity within the CKD group. CKD outlier samples seemed to diverge from controls due
to the presence of different taxa as shown by high distance values among CKD outlier
communities.

Demographic and clinical comparisons between CKD-outliers and CKD-C showed no significant
differences. On the other hand, CKD-C displayed increased α-diversity as shown by the number
of observed and estimated OTUs, as well as the NP Shannon and inverse Simpson indices.
Bivariate correlation analysis identified an association between alpha diversity and dialysis
vintage in the CKD subsets. Nevertheless, this correlation was unable to explain the alpha
diversity differences since the time in dialysis did not differ between CKD-outliers and CKD-C
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subjects. This could be due to the reduced sample size of both CKD-outliers (n=6) and CKD-C
(n=8).

In summary, in this aim we demonstrate that microbiological profiles do not explain the
purported increased prevalence of periodontitis in CKD. Therefore, other CKD-related modifiers
should be considered to uncover the mechanisms behind this association. In fact, typical CKD
factors such as diabetes status, uremic state, serum inflammatory marker levels, as well as
nutrition deficiencies should be further evaluated to better assess the means through which such
association occurs. Investigations that evaluate the microbiome of CKD patients with and
without CP in comparison to control non-CKD patients are also needed to elucidate differences
that could predispose renal patients to periodontal destruction. Although this study demonstrates
no differences in the subgingival microbiome associated with periodontitis in CKDs and
controls, it is still possible that the microbiomes associated with health differ and increased
representation of periodontitis-associated species is present in CKDs before disease occurs,
increasing the risk for CP in CKD.

6.2 Overall improved clinical characteristics result from SRP in Control and CKD subjects
The second objective of this work was to evaluate the clinical and microbial outcomes of SRP in
CP subjects with and without CKD. These cohorts represent subjects who completed initial
periodontal therapy. While 15 Control subjects were followed throughout the whole study, some
CKD patients were deceased or withdrawn due to worsening of their systemic compromise. As a
result, only 6 CKD patients could be evaluated at the end of the study. At pre-SRP, similar
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clinical and microbiological parameters were found to not markedly differ between the two
groups, similar to results described in Aim 1. However, age was increased in the CKD group in
the Aim 2 cohorts. This is a potential confounder for the microbiological analysis since, in
subjects with aggressive and chronic periodontitis, significant higher counts of red complex
bacteria were reported in older subjects compared to younger patients [154]. As results show,
however, the CKD group did not have higher baseline levels of periodontal pathogens.

The clinical outcomes of non-surgical periodontal therapy in Control subjects revealed drastic
improvements. Specifically, significant decreases in mean PD (0.7mm) and CAL (0.7mm) were
found from pre- to post-SRP. In addition, the percentage of sites with BoP, PS, PD and CAL
≥4mm decreased considerably, while the number of sites with PD and CAL 1-3mm increased.
These results are in line with classic [155-157] and more recent reports [86, 158]. Our study
rendered an average reduction of 0.7mm both in mean PD and CAL from pre- to post-SRP.
These results are similar to the aproximate 1.0mm reduction described in initial studies [155157] and the average reduction of 0.5mm in PD/CAL reported by more recent works [86, 158].
A mean reduction of 20% was seen in BoP and PS of Control patients. Indeed, a 30% reduction
in BoP and 20% decrease in PS have been described by previous reports [86, 156, 158].

The response of the CKD cohort to SRP also showed a trend for improvement. Mean CAL and
the percentage of sites with BoP and CAL>5mm decreased from pre to post therapy. PD
distribution and mean PD, as well as the percentage of sites with PS showed a trend to decrease
in the same period. However, the lack of significance in the improvement of some clinical
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parameters may derive from the small size of the CKD population evaluated by this work (n=6).
Alternatively, initial therapy is less effective in the CKD subjects. Although comparisons of the
delta changes in clinical outcomes between groups showed no statistically significant differences
in the magnitude of change, there was a tendency for deeper pockets (PD>5mm) to show less of
a change in PD post-SRP in the CKD group than in controls. This question can only be definitely
answered, however, with a greater sample size.

Only two studies have evaluated the outcomes of SRP in CKD (pre-dialysis) in comparison to
non-CKD cohorts [113, 135] finding similar improvements in periodontal clinical parameters
[113] as well as subgingival microbial compositions for CKD and non-CKD populations [135].
In the Artese et al. (2010) study, when post-SRP measurements of clinical parameters (PD, CAL,
percentage of sites with BoP and PS) were subtracted from pre-SRP values and compared in
Control versus CKD subjects, no discrepancy was found for any evaluated characteristics.
Similar outcomes were found when the post-treatment values were compared between CKD and
systemically healthy subjects. These authors suggested that the response to therapy occurred in a
similar fashion resulting in no evident clinical differences between groups [113]. However, their
definition of Chronic Periodontitis included CAL ≥4mm in 4 or more sites of 3 different teeth,
with the presence of BoP. Such lenient criteria may have masked disease severity [2, 159]. It is
known that less severely diseased sites respond in a more moderate fashion to initial therapy
[160, 161]. Therefore, evaluation of clinical outcomes between CKDs and controls should be
accomplished in populations with moderate to severe disease as those present in the current
study.
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6.3 Non-surgical periodontal therapy does not drastically change the composition of
subgingival communities although it decreases the abundance and prevalence of certain
disease-associated species
Microbial analyses from pre- to post-SRP encompassed alpha and beta diversity evaluations, as
well as the assessment of relative abundance and prevalence of OTUs. The evaluation of 15
samples from the Control group only resulted in 886 OTUs. Surprisingly, although increased
alpha diversity is associated with periodontitis severity [31, 38, 39], initial therapy did not
drastically alter community alpha diversity metrics. Similarly, and showing that initial therapy
did not dramatically change global community structure and composition, we observed no
differences in beta diversities from pre- to post-SRP.

Prevalence and relative abundance evaluations of Control samples at pre- and post-SRP showed
that recognized periodontitis-associated taxa (i.e.: P. micra, P. intermedia, E. nodatum, P.
gingivalis, T. denticola, T. forsythia, F. alocis), decreased post-SRP. OTUs that increased at
post-SRP included Streptococcus sp. OT071, Capnocytophaga leadbetteri, Prevotella
saccharolytica, Actinomyces spp., and Rothia spp., which are neither health nor diseaseassociated or are health-associated. Similar results were reported in studies that performed DNADNA hybridization of subgingival samples in CP patients [81, 82, 86]. These authors reported a
decrease in the levels of red complex bacteria, as well as C. rectus and E. nodatum mainly at 3
and 6 months post-SRP, which were maintained until the 12-month post-therapy mark (a
quarterly supportive periodontal therapy protocol was established from 3-12 months). In
addition, they found increased post-SRP prevalence of A. naeslundii, A. odontolyticus, S. mitis,
and Capnocytophaga sp. [81, 82, 86, 158]. While the microbial detection ability of the above-
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mentioned studies was limited (i.e. 25-40 species), our work is the first to evaluate the outcomes
of initial therapy using pyrosequencing. Our results using this novel approach revealed that,
despite the clear clinical improvements and the decrease in prevalence/abundance of certain
species from pre- to post-SRP, the overall composition of the subgingival microbiome of CP
patients did not change drastically. In particular, of the 20 most abundant OTUs before SRP, 15
were still present in the top 20 post-treatment. This is a surprising outcome and indicates that
global community profiles do not need to mimic a microbiome associated to periodontal health
for positive clinical results to be achieved. A more interesting question, however, is whether
these decreased levels of selected periodontitis-associated species are the desirable outcomes of
therapy. It seems from the observed lack of drastic changes in global community profiles that
recolonization of pathogenic communities after therapy could easily occur. This is exemplified
by the lack of sustained results in the absence of patient compliance and strict maintenance [162164]. An ideal periodontal treatment would be one that completely changes microbial profiles to
those seen in health. Standard initial therapy, however, does not seem to achieve this objective.

6.4 The microbiological response of Control and CKD subjects to non-surgical periodontal
therapy follows opposite trends
Analyses of 6 samples from the CKD group rendered 537 OTUs, with no observed differences in
alpha and beta diversities from pre to post-SRP. Increased relative abundance of 5 taxa was
found after therapy, whereas prevalence analysis revealed no differences from before to after
SRP in this group. In addition, similar to the results from the Control cohort, red complex
bacteria and several members of the Fusobacterium nucleatum sp. predominated within the 20
most abundant OTUs at pre-SRP. After initial treatment, Prevotella nigrescens was the most
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abundant OTU in CKD samples. Increased levels of post-therapy P. nigrescens have been
recently described in CKD patients [135]. Indeed, as our analysis of the magnitude of change
between CKDs and controls shows, Prevotella spp. did not respond to therapy favorably in
CKDs. As with the Control group, only minor changes in the microbiome profile of CKD
subjects were noted from pre- to post-SRP (11 out of the 20 most abundant OTUs at pre-SRP
remained as part of the top 20 taxa at post therapy). However, inferrences are difficult to be
drawn from the analyses of this group due to its limited sample size.

In order to eliminate interference from the inter-subject variablity of our samples, we conducted
paired analyses of the ß-diversity change from pre- to post-SRP between Control and CKD
groups. As can be seen in Figure 30, structure (Weighted Unifrac and ThetaYC) and composition
(Unweighted Unifrac and Jaccard) analyses showed the same degree of community change in
microbial communities from before to after therapy in both CKD and Control samples.

These results suggested that the microbiological outcomes of non-surgical therapy were similar
between Control and CKD cohorts. However, when we compare the magnitude of change for the
most abundant OTUs at baseline, we observed clear trends that differentiated the microbiological
response between CKDs and controls. While in Controls most species tended to decrease in
abundance after SRP, in CKDs the trends observed were the opposite, towards an increase after
SRP. Although the small sample size of the CKD group possibly precluded finding statistically
significant differences for most of these parameters, these trends suggest that control of the
infection burden in CKDs by conventional initial therapy is even more difficult to achieve. It is
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then possible that the moderate clinical outcomes observed in CKDs are a result of the failure of
initial therapy to modify the levels of disease-associated species with the underlying systemic
condition serving as a modifier for pocket recolonization.

7. Conclusions
From the work reported herein, it can be concluded that:
• In matched CP subjects with and without CKD, unique subgingival microbiome
signatures were not associated with periodontitis in CKD.
• Non-surgical periodontal therapy rendered significant clinical improvements in Control
subjects, and more moderate clinical improvements in CKD subjects. These results,
however, are qualified by the small sample size of the CKD group.
• In this limited sample, it was observed that the microbiological response of Control and
CKD subjects to non-surgical periodontal therapy differed, with CKD subjects showing
trends for more moderate decreases in periodontitis-associated species like P. gingivalis and
T. forsythia than controls, while other disease-associated species, noticeably Prevotella spp.
and Treponema spp., did not respond favorably to initial therapy in the CKD group.
• Our results then suggest that CKD is not a modifier of the subgingival microbiome in
established periodontitis lesions but CKD could potentially compromise the clinical and
microbiological outcomes of initial periodontal therapy.
• Remarkably, our study also shows that despite clinical improvements, and some expected
changes in the proportions and prevalence of individual disease and health-associated taxa,

74

non-surgical periodontal therapy does not drastically change the subgingival microbiome to
one similar to health.
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